✦ The Association for Accessible Medicines (AAM) filed an amicus brief May 13 in support of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) remaining law if the Affordable Care Act (ACA) is invalidated. The BPCIA established the 351(k) biosimilar pathway, and AAM asserted that the legislation is “a functionally independent part” of the ACA. If the BPCIA is invalidated, “a decade of progress by AAM and its members would be lost,” stated the brief. View the brief at https://bit.ly/2zWVDlf.
✦ With its first-in, first-out accounting methodology for specialty drug pricing, Navitus Health Solutions saved plan sponsors an average of 8% on those drugs in 2019 before price hikes due to inflation, according to its 2019 Drug Trend Report, released on May 18. Among other findings, the company’s specialty pharmacy, Lumicera Health Solutions, saved plan sponsors more than $1.5 million through its split-fill program. Download the report at www.navitus.com.